China Resources Pharmaceutical Shareholders Approve Sales Framework and New Articles at 2026 EGM

China Resources Pharmaceutical Group Ltd. ( (HK:3320) ) has shared an announcement.

China Resources Pharmaceutical Group Limited announced that all resolutions proposed at its first extraordinary general meeting of 2026, held on 6 February, were duly approved by shareholders by way of poll. The meeting approved the Sales Framework Agreement 2026/2028, including its associated annual caps and authorisations for directors to execute related documents, with interested controlling shareholder CR Holdings and its associates abstaining from voting on this connected-transaction resolution in accordance with listing rules. Shareholders also passed a special resolution to adopt new Articles of Association to replace the existing ones with immediate effect after the meeting, further formalising the company’s governance framework; no shareholders were required to abstain or voted against the resolutions in significant numbers, underscoring broad investor support for both the transaction arrangements and the corporate governance changes.

The most recent analyst rating on (HK:3320) stock is a Hold with a HK$5.00 price target. To see the full list of analyst forecasts on China Resources Pharmaceutical Group Ltd. stock, see the HK:3320 Stock Forecast page.

More about China Resources Pharmaceutical Group Ltd.

China Resources Pharmaceutical Group Limited is a Hong Kong–incorporated pharmaceutical company listed on the Stock Exchange of Hong Kong. It operates in the healthcare and pharmaceutical sector, with its share capital widely held but controlled by CR Holdings through subsidiaries CRH (Pharmaceutical) Limited and Commotra Company Limited, which together hold a majority stake in the company.

Average Trading Volume: 12,510,133

Technical Sentiment Signal: Sell

Current Market Cap: HK$28.15B

For an in-depth examination of 3320 stock, go to TipRanks’ Overview page.